289503-27-1

Basic information

• Product Name: 2-amino-4-(N-tosyl-6'-bromo-3'-indolyl)pyrimidine
• Synonyms: 2-amino-4-(N-tosyl-6'-bromo-3'-indolyl)pyrimidine
• CAS NO: 289503-27-1
• Molecular Weight: 443.324
• Mol File: 289503-27-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-amino-4-(N-tosyl-6'-bromo-3'-indolyl)pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-4-(N-tosyl-6'-bromo-3'-indolyl)pyrimidine(289503-27-1)
• EPA Substance Registry System: 2-amino-4-(N-tosyl-6'-bromo-3'-indolyl)pyrimidine(289503-27-1)

Safety Data

• Hazardous Substances Data: 289503-27-1(Hazardous Substances Data)

Upstream product

• 50-01-1 guanidine hydrochloride 
• 341998-58-1 (E)-1-(6-bromo-1-tosyl-1H-indol-3-yl)-3-(dimethylamino)prop-2-en-1-one 
• 52415-29-9 6-bromo-1H-indole 
• 224434-85-9 1-(6-bromo-1-tosyl-1H-indol-3-yl)ethan-1-one 
• 98-59-9 p-toluenesulfonyl chloride 
• 316181-82-5 1-(6-bromo-1H-indol-3-yl)ethan-1-one 
• 289503-25-9 N-tosyl-3,6-dibromoindole 
• 189265-99-4 6-bromo-1-(4-methylphenylsulfonyl)-1H-indole 
• 3993-78-0 2-amino-4-chloropyrimidine 
• 289503-26-0 N-tosyl-6-bromo-3-indolylboronic acid 

Relevant articles and documents

Meridianin D Analogues Display Antibiofilm Activity against MRSA and Increase Colistin Efficacy in Gram-Negative Bacteria

In the last 30 years, development of new classes of antibiotics has slowed, increasing the necessity for new options to treat multidrug resistant bacterial infections. Development of antibiotic adjuvants that increase the effectiveness of currently available antibiotics is a promising alternative approach to classical antibiotic development. Reports of the ability of the natural product meridianin D to modulate bacterial behavior have been rare. Herein, we describe the ability of meridianin D to inhibit biofilm formation of methicillin-resistant Staphylococcus aureus (MRSA) and to increase the potency of colistin against colistin-resistant and sensitive Gram-negative bacteria. Analogues were identified that are capable of inhibiting and dispersing MRSA biofilms and lowering the colistin MIC to below the CLSI breakpoint against Acinetobacter baumannii, Klebsiella pneumoniae, and Escherichia coli.